TL;DR (the editorial verdict)
AI mental health is two different markets, and the most common mistake we see in published comparisons is mixing them. Tools your therapist uses to write notes are not the same category as tools you hand to a patient at discharge. We split this guide accordingly, and we recommend you treat the two halves as separate purchases.
Best therapy-specific AI scribe (provider): Mentalyc. DAP/SOAP/BIRP/GIRP support, $19.99 to $69.99/mo, HIPAA-attested, direct affiliate. The default pick for a solo or small-group therapist who wants notes done by the time the session ends.
Best enterprise behavioral-health AI (provider): Eleos Health. Behavioral-health-only ambient AI with voice analytics, EHR-embedded, 5-seat minimum. Built for community mental health agencies and group practices, not solo clinicians.
Best evidence-backed patient-side chatbot: Wysa. NHS DTAC certified, deployed by NHS, Singapore MOH, and Aetna. CBT, DBT, and mindfulness modules with a published evidence base. The pick when a clinician wants a peer-reviewed app to recommend between sessions.
Best consumer brand for patient referral: Headspace. The largest mental-health consumer brand, with the AI companion Ebb launched in 2024 for Core and Care subscribers. Patients have heard of it, which matters for adherence.
Methodology: we aggregated public reviews from clinicians on r/psychotherapy, r/therapists, Doximity, and G2; cross-checked vendor documentation and peer-reviewed literature; and signed off through a board-certified physician on our editorial team. See our [full methodology](https://healthcareai.brainbyt.es/methodology).
Why this guide splits provider and patient
Most "best AI for mental health" lists rank Mentalyc next to Woebot. That comparison is meaningless. One is a billing-side documentation tool; the other is a CBT chatbot a patient uses on their phone at 2am. The buyer is different, the safety profile is different, and the evidence bar is different. We split this guide because clinicians need both lists in 2026, but they need them clean.
Provider-side tools (what therapists buy for themselves)
These sit in the clinician workflow. The therapist is the user; the patient is the subject of a note or analytics signal. Buying criteria are pricing per provider, HIPAA + BAA, EHR integration, and note format coverage (DAP, SOAP, BIRP, GIRP). Examples: Mentalyc, Upheal, Blueprint, Supanote, JotPsych, Lyssn, Eleos Health.
Patient-side tools (what clinicians recommend to patients)
These are consumer apps. The patient is the user. The clinician's job is recommending the right one and explaining what it is not. Buying criteria for the recommendation: published RCT evidence, regulatory status (NHS DTAC, FDA Breakthrough), safety routing for suicidal ideation, and a credible vendor. Examples: Wysa, Woebot, Headspace, Youper, Limbic, Rosebud, Replika.
A safety note that should not need stating: none of the patient-side tools below are a substitute for therapy, and none replace acute-crisis intervention. If a patient discloses suicidal ideation, the app's job is to route to a human service (988 in the US, Samaritans in the UK, regional equivalents). We checked which ones actually do this. Some do not.
How we evaluated 22 AI mental health tools
Same six-source method we use across the Healthcare AI Hub:
Vendor documentation (30%): pricing pages, security attestations, BAA terms, note-format coverage.
Public review aggregators (20%): G2, Capterra, App Store and Play Store ratings for patient-side apps.
Clinician community sentiment (20%): r/psychotherapy, r/therapists, r/Psychiatry, Doximity threads. Each mention gets sentiment-analyzed; URLs logged.
Peer-reviewed literature (15%): PubMed-indexed studies. We weighted RCTs over observational and pre-print work.
Vendor stability signals (10%): funding, leadership stability, marketplace certifications (NHS DTAC, FDA, SOC2).
Specialty-society guidance (5%): APA, NICE, NHS, Royal College of Psychiatrists positions on digital therapeutics.
Pricing changes fast. If you spot stale data, email corrections@healthcareai.brainbyt.es and we publish a correction within seven business days.
Provider pick 1: best therapy-specific AI scribe, Mentalyc
Mentalyc is the default recommendation for solo and small-group therapists who want notes that match how psychotherapy is actually documented. The product was built therapy-first, not general-medicine-with-a-mental-health-template. That shows in the note formats: DAP, SOAP, BIRP, GIRP, intake assessments, and treatment plans are all native, not afterthoughts.
Pricing is transparent: $19.99 to $69.99 per month depending on session volume. HIPAA-attested. The vendor signs BAAs on all tiers, which we verified. There is a direct affiliate program, which is part of why we recommend it; the incentive to point a therapist at a tool that does not fit (and watch the cancellation a month later) is bad for both sides, so the recommendation has to fit.
The note quality, in aggregated reviews from r/therapists and Mental Health Match forum threads through Q1 2026, is consistently rated above generic medical scribes for therapy-specific language. Therapists in those threads called out reflective listening, intervention tagging, and risk-statement capture as the three things Mentalyc gets right that the general scribes miss.
Pros
Therapy-native note formats (DAP, SOAP, BIRP, GIRP, intake, treatment plan).
Sub-$70/month transparent pricing; no enterprise gate.
HIPAA-attested with BAA across all tiers.
Strong therapy-language capture (interventions, reflective statements, risk).
Cons
No deep EHR write-back; mostly copy-paste or basic integrations.
Limited group-therapy and family-session support compared to JotPsych.
Smaller vendor than enterprise alternatives; less stability runway than Eleos Health.
Best for: Solo LCSWs, LMFTs, LPCs, and psychologists in private practice or 2 to 5 clinician groups who want therapy-native notes without an enterprise sales cycle.
Read the full Mentalyc review →
Provider pick 2: best enterprise behavioral-health AI, Eleos Health
Eleos Health is the enterprise answer. Founded in 2020, HQ in the US, HIPAA and SOC2 Type II attested, with a 5-seat minimum that tells you everything about the buyer: community mental health centers, large group practices, and agencies with a clinical leadership layer making the decision.
What sets Eleos apart from the broader scribe market is the "CareOps" layer. The product captures ambient session audio, generates the note, and runs voice analytics on top: talk-time ratios, intervention mix, fidelity scoring against modalities like CBT or motivational interviewing. For supervisors running quality programs at scale, that analytics layer is the reason to pick Eleos over a pure-scribe alternative.
The integration story is the other reason. Eleos embeds into the EHR rather than living alongside it. For agencies on NextGen, Netsmart, or Welligent, that integration depth is the difference between a tool that gets adopted and one that gets quietly dropped in month four.
Pros
Purpose-built for behavioral health from day one, not a general scribe with a mental-health skin.
Voice analytics and CareOps layer for supervision and quality.
Deep EHR embedding (Netsmart, NextGen, Welligent and others).
HIPAA + SOC2 Type II attested, enterprise security review-ready.
Cons
5-seat minimum; not realistic for solo practice.
Enterprise pricing only, no transparent per-seat number on the marketing site.
Onboarding takes weeks, not hours, with security and EHR integration phases.
Best for: Community mental health agencies, 10+ clinician group practices, and behavioral-health systems where supervision and fidelity scoring matter as much as the note.
Read the full Eleos Health review →
Patient pick 1: best evidence-backed chatbot, Wysa
Wysa is the patient-side recommendation when a clinician wants the strongest evidence and regulatory profile available in 2026. The app uses a friendly penguin character to deliver CBT, DBT, and mindfulness exercises through chat. It is deployed by the UK National Health Service, Singapore's Ministry of Health, and Aetna in the US. The NHS DTAC (Digital Technology Assessment Criteria) certification is not trivial; it requires evidence on clinical safety, data protection, technical security, and interoperability.
Pricing is freemium with a Premium tier around $74.99 per year. Most patients you recommend it to will use the free version meaningfully before deciding. That matters for adherence: friction at the paywall is a known dropout point for digital therapeutics.
On safety: Wysa routes suicidal ideation disclosures to local crisis services rather than trying to handle them in-app. We verified this behavior in May 2026. That single design choice is the floor we expect from any patient-side app we recommend. Several others in this category did not pass that check.
Pros
NHS DTAC certified, deployed by NHS, Singapore MOH, Aetna.
Multiple peer-reviewed studies on anxiety and depression outcomes.
Safe crisis routing (988 in US, Samaritans in UK, regional equivalents).
Free tier is genuinely useful, not a 7-day trial.
Cons
Penguin persona reads as childish for some adults; not all patients accept the framing.
Premium content paywall can frustrate motivated users.
Limited cultural localization outside English-speaking markets.
Best for: Patients between sessions who need a coping-skills tool, especially in CBT-aligned care plans. Clinicians who want the most clinically defensible app to put on a recommendation list.
Patient pick 2: best consumer brand for patient referral, Headspace
Headspace is the recommendation when brand familiarity matters more than the deepest CBT toolkit. Founded in 2010, US-based, with the largest mental-health app brand recognition in the consumer market. Pricing is $12.99 per month or $69.99 per year. The Impact affiliate program means clinicians whose websites recommend it can disclose the relationship cleanly.
The AI piece is Ebb, launched in 2024 for Core and Care subscribers. Ebb is a reflective listening companion, not a CBT chatbot. It will not deliver structured exercises the way Wysa does. What it does well is sit alongside the meditation library and the sleep content, which is the actual reason most patients open the app.
A pragmatic editorial point: patient adherence in the wild is driven by whether the patient remembers the app exists. Headspace wins on memorability. We routinely see patients in aggregated forum reviews say they tried Wysa for a week and went back to Headspace because it was already on their phone. That is not a clinical-evidence argument; it is a behavioral one. Both factors matter.
Pros
Largest mental-health consumer brand; high patient name recognition.
AI companion Ebb for Core and Care subscribers (2024 launch).
Strong meditation, sleep, and mindfulness library independent of the AI layer.
Impact affiliate program for transparent clinician referral economics.
Cons
Ebb is companion-style, not structured CBT delivery.
Crisis-routing behavior is weaker than Wysa by our 2026 review.
Annual pricing locks in a year for patients who may try and drop.
Best for: Patients in stress-management, sleep, and general-wellness lanes who will not stick with a clinical-feeling chatbot. Useful as a low-friction first recommendation.
Read the full Headspace review →
What to look for: 5-criteria buyer's guide
The criteria differ between sides. We give both.
Criterion 1: workflow fit (provider) vs daily-use fit (patient)
On the provider side, this is EHR integration depth and note-format coverage. Eleos Health embeds into agency EHRs. Mentalyc lives alongside whatever you use. Supanote writes back natively to therapy-specific EHRs via "Super Fill". The right answer depends on what EHR your practice already runs.
On the patient side, this is whether the patient will open the app on day 8, 30, and 90. Reviews on r/Anxiety and r/depression in Q1 2026 show median dropout inside 14 days for most apps. The exceptions are apps with daily habits already attached (Headspace meditation, Rosebud journaling) or apps with strong reminder UX.
Criterion 2: compliance and certification
Provider side: HIPAA + BAA is the floor, not a feature. SOC2 Type II is becoming standard for anything an agency will sign. Eleos Health, Upheal, Mentalyc, and Blueprint all clear HIPAA. We will not recommend a scribe that cannot show a BAA.
Patient side: the certifications that actually mean something are NHS DTAC (Wysa, Limbic) and FDA Breakthrough Device (Woebot). Consumer apps without one of these have a much weaker evidence floor.
Criterion 3: pricing transparency
A vendor that hides pricing behind a sales call is signaling that the price is high enough to need a sales call. That is fine for enterprise Eleos Health or Blueprint buyers. It is a yellow flag for solo-practice tools. Mentalyc ($19.99 to $69.99/mo), Upheal (from $29/mo), Supanote ($30 to $50/mo), and Quill Therapy Notes ($20/mo) all post numbers. Use them.
Criterion 4: evidence quality (patient side, dominant criterion)
This is where the patient-side market splits hardest. Woebot has 14 published RCTs and an FDA Breakthrough Device designation, the strongest evidence base in the category. Wysa has NHS deployment plus a meaningful peer-reviewed footprint. Limbic is integrated into NHS IAPT triage with published outcome data.
Then there are tools we will not put in the picks list because the evidence is thin: Replika is a companion app with documented safety incidents around romantic-attachment dynamics. Slingshot AI (Ash) launched in 2023 with foundation-model-based therapy and minimal published RCT data. Sonia has a 6-week GAD program but no peer-reviewed efficacy publication we could locate. Recommend with proportional caution.
Criterion 5: vendor stability
Woebot pivoted from consumer to B2B in 2024, which is a useful lesson: a tool a clinician recommends today may not be available to that patient in 18 months. Headspace and Wysa have the longest operating runways in the patient category. On the provider side, Eleos Health is the most-funded with deepest enterprise customer base; Blueprint and Upheal are growing.
How the field has shifted in 2026
The biggest signal in 2026 is the consumer-to-B2B pivot. Woebot led that move in 2024, pulling its consumer app and selling exclusively to health plans and providers. We expect at least one more of the 2023 generation of patient-side chatbots to make the same call in 2026 as direct-to-consumer mental-health subscription economics get harder. On the provider side, the therapy-scribe category has matured fast: Mentalyc, Upheal, Supanote, and Eleos Health now have product-market fit signals strong enough that we expect consolidation by the end of the year.
Comparison table
Full side-by-side comparison: see the complete tool table.
Frequently asked questions
Are AI mental health tools a substitute for therapy?
No. Every patient-side tool in this guide, including Wysa and Woebot with the strongest evidence, is positioned by its own vendor as a complement to professional care, not a replacement. The APA, NICE, and NHS digital therapeutics positions are all consistent on this point. When you recommend one of these to a patient, the script is "use this between our sessions for the specific skill we worked on", not "use this instead of coming in".
Which AI mental health tool has the most clinical evidence?
Woebot has the deepest peer-reviewed RCT footprint in the category with 14 published trials and an FDA Breakthrough Device designation. The catch is that Woebot pivoted to B2B-only in 2024, so a patient cannot download it directly. For a recommendable consumer app with strong evidence, Wysa is the next best answer, with NHS DTAC certification and multiple published anxiety and depression outcome studies.
Can a patient use an AI chatbot during a suicidal crisis?
No. AI chatbots are not crisis-response systems and should not be used as one. The appropriate response is 988 in the US, Samaritans (116 123) in the UK, or the local equivalent. We checked which apps route crisis disclosures appropriately in May 2026: Wysa, Woebot, and Limbic all route to local crisis services. Several consumer-companion apps do not handle this well; we do not recommend those for patients with any active risk profile.
Is HIPAA compliance enough for an AI therapy scribe?
It is the floor, not the ceiling. HIPAA with a signed BAA is the minimum we will recommend on the provider side. The additional questions to ask: does the vendor train models on your session data (most reputable ones do not, but verify); is SOC2 Type II in place for larger agencies; does the BAA cover subprocessors. Eleos Health, Mentalyc, Upheal, and Blueprint all answer these clearly. Tools without clear BAA documentation are not safe to put session audio through.
What is the right pricing benchmark for a solo therapist?
$20 to $70 per month is the current market for a therapy-native scribe a solo clinician would actually use. Below $20, expect compromises on note quality or format coverage. Above $100, you should be getting either enterprise analytics (Eleos Health) or psychiatry-specific features (JotPsych at $150/mo, fair for med-management workflows). Mentalyc at $19.99 to $69.99 sits in the sweet spot for general therapy.
Should I recommend the same app to every patient?
No, and this is the most common mistake we see in published clinician guidance. Match the tool to the care plan. CBT-aligned skill practice between sessions: Wysa. Mindfulness and sleep: Headspace. Journaling habit: Rosebud. Mood tracking with biometric sync: Youper. A blanket "try a mental health app" is poor referral practice; specificity drives adherence.
Related reading on Healthcare AI Hub
Methodology and disclosure
This article aggregates public reviews from clinicians on r/psychotherapy, r/therapists, r/Psychiatry, Doximity, and G2; cross-checks vendor documentation and peer-reviewed literature; and is signed off by our board-certified physician advisor. We may earn a commission when a clinician or patient signs up through outbound links, at no extra cost to them. Full policy at /affiliate-disclosure.